- Home
- ACLX vs CNS Comparison
ACLX vs CNS Comparison
Compare ACLX & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- CNS
- Stock Information
- Founded
- ACLX 2015
- CNS 1986
- Country
- ACLX United States
- CNS United States
- Employees
- ACLX N/A
- CNS N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- CNS Investment Managers
- Sector
- ACLX Health Care
- CNS Finance
- Exchange
- ACLX Nasdaq
- CNS Nasdaq
- Market Cap
- ACLX 4.1B
- CNS 4.0B
- IPO Year
- ACLX 2022
- CNS 2004
- Fundamental
- Price
- ACLX $71.28
- CNS $76.27
- Analyst Decision
- ACLX Strong Buy
- CNS Hold
- Analyst Count
- ACLX 14
- CNS 3
- Target Price
- ACLX $114.75
- CNS $82.00
- AVG Volume (30 Days)
- ACLX 522.3K
- CNS 207.2K
- Earning Date
- ACLX 08-07-2025
- CNS 10-15-2025
- Dividend Yield
- ACLX N/A
- CNS 3.26%
- EPS Growth
- ACLX N/A
- CNS 23.33
- EPS
- ACLX N/A
- CNS 3.15
- Revenue
- ACLX $56,979,000.00
- CNS $543,579,000.00
- Revenue This Year
- ACLX N/A
- CNS $7.32
- Revenue Next Year
- ACLX $108.81
- CNS $8.15
- P/E Ratio
- ACLX N/A
- CNS $24.19
- Revenue Growth
- ACLX N/A
- CNS 11.54
- 52 Week Low
- ACLX $47.86
- CNS $68.99
- 52 Week High
- ACLX $107.37
- CNS $110.67
- Technical
- Relative Strength Index (RSI)
- ACLX 52.20
- CNS 54.20
- Support Level
- ACLX $69.00
- CNS $71.31
- Resistance Level
- ACLX $74.74
- CNS $75.51
- Average True Range (ATR)
- ACLX 3.47
- CNS 1.97
- MACD
- ACLX -0.19
- CNS 0.05
- Stochastic Oscillator
- ACLX 56.94
- CNS 73.41
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.